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Introduction: Disease activity, severity and comorbidity contribute to increased mortality in patients with
rheumatoid arthritis (RA). We evaluated the impact of age at disease onset on prognostic risk factors and treatment
in patients with early disease.
Methods: In this study, 950 RA patients were followed regularly from the time of inclusion (<12 months from
symptom onset) for disease activity (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender and/or
swollen joints, Visual Analogue Scale pain and global scores, and Disease Activity Score in 28 joints (DAS28)) and
function (Health Assessment Questionnaire (HAQ)). Disease severity, measured on the basis of radiographs of the
hands and feet (erosions based on Larsen score), extraarticular disease, nodules, and comorbidities and treatment
(disease-modifying antirheumatic drugs (DMARDs), corticosteroids, biologics and nonsteroidal anti-inflammatory
drugs) were recorded at the time of inclusion and at 5 years. Autoantibodies (rheumatoid factor, antinuclear anti-
bodies and antibodies against cyclic citrullinated peptides (ACPAs)) and genetic markers (human leucocyte antibody
(HLA) shared epitope and protein tyrosine phosphatase nonreceptor type 22 (PTPN22)) were analysed at the time
of inclusion. Data were stratified as young-onset RA (YORA) and late-onset RA (LORA), which were defined as being
below or above the median age at the time of onset of RA (58 years).
Results: LORA was associated with lower frequency of ACPA (P < 0.05) and carriage of PTPN22-T variant (P < 0.01),
but with greater disease activity at the time of inclusion measured on the basis of ESR (P < 0.001), CRP (P < 0.01) and
accumulated disease activity (area under the curve for DAS28 score) at 6 months (P < 0.01), 12 months (P < 0.01) and 24
months (P < 0.05), as well as a higher HAQ score (P < 0.01) compared with YORA patients. At baseline and 24 months,
LORA was more often associated with erosions (P < 0.01 for both) and higher Larsen scores (P < 0.001 for both).
LORA was more often treated with corticosteroids (P < 0.01) and less often with methotrexate (P < 0.001) and biologics
(P < 0.001). YORA was more often associated with early DMARD treatment (P < 0.001). The results of multiple regression
analyses supported our findings regarding the impact of age on chosen treatment.
Conclusion: YORA patients were more frequently ACPA-positive than LORA patients. LORA was more often associated
with erosions, higher Larsen scores, higher disease activity and higher HAQ scores at baseline. Nevertheless, YORA was
treated earlier with DMARDs, whilst LORA was more often treated with corticosteroids and less often with DMARDs in
early-stage disease. These findings could have implications for the development of comorbidities.* Correspondence: solveig.wallberg.jonsson@medicin.umu.se
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease with an age-related incidence. It is present in all eth-
nic populations and at all ages, with prevalence increasing
together with age and reaching approximately 2% in a
geriatric population [1]. RA is a progressive, destructive
joint disease leading to reduced physical function, im-
paired quality of life and increased risks for comorbidity
and premature death if left untreated [2-8]. The presence
of different autoantibodies, particularly antibodies against
cyclic citrullinated peptides and proteins (ACPAs) indi-
cates an unfavourable prognosis regarding the disease
course [9,10]. Age at disease onset has been implicated as
an indicator of disease activity, disease severity, comorbid-
ity and effective pharmacological treatment [11-15]. Re-
searchers in previous studies in this field have reported
that patients with late-onset RA (LORA) have a more be-
nign form of the disease than those with young-onset RA
(YORA) [16-19]. Some of these studies were performed
before the 1987 American Rheumatism Association cri-
teria [20] were introduced, and some patients had
probably received an alternative diagnosis, for example,
polymyalgia rheumatica. The results of studies conducted
during recent decades that have directly compared LORA
and YORA have been inconsistent with earlier studies.
Despite differing cutoff ages, the prognosis for LORA pa-
tients has not been reported to be very different from that
for YORA patients in terms of Disease Activity Score in
28 joints (DAS28), Health Assessment Questionnaire
(HAQ) score and the degree of radiographically detected
joint damage. Some researchers have even described a
poorer prognosis in patients with LORA [11,12,21,22].
Few of these previous publications included individuals
with very early RA.
According to published studies, elderly RA patients do
not receive the same treatment as younger RA patients,
despite having either greater or equivalent disease activ-
ity [13,15,23-25]. These data are at variance with YORA
patients, who are generally treated adequately and in ac-
cordance with national guidelines [26-28]. A rapid diag-
nosis of genuine RA is important, however, to initiation
of early treatment and consequently to achieve the best
prognosis and clinical outcome for the patient [29-32].
We hypothesized that age at the onset of RA influences
prognosis and any treatment prescribed. Thus, our aim in
the present study was to evaluate the impact of age at dis-
ease onset on prognostic risk factors, disease progression
and pharmacological treatment in a large inception cohort
of patients with RA from northern Sweden.
Methods
To identify potential participants in our study, we re-
ferred to the nationwide Swedish Early RA Registry, a
part of the Swedish Rheumatology Quality Register [33].All eligible patients from the four northernmost counties
of Sweden diagnosed with early RA (that is, symptomatic
for <12 months) since December 1995 who met the 1987
American Rheumatism Association classification criteria
[20] were consecutively included in our large observa-
tional study on the progression of RA, including complica-
tions and comorbidities. By February 2011, we had
registered 950 patients (649 women and 301 men) with
newly diagnosed incident early RA who had been included
in the study at the time of RA diagnosis (baseline, T0).
From among these patients, 665 had been followed for 5
years (T5). All patients had been assessed regularly with a
clinical examination performed by their local rheumatolo-
gists during this follow-up period, together with routine
laboratory tests and radiographs of their hands and feet.
The regional Ethics Committee at the University Hospital
of Umeå approved this study, and all participants gave
their written informed consent in accordance with the
Declaration of Helsinki.
According to the criteria for inclusion of individuals in
the Swedish Early RA Registry, the following data were
recorded at baseline and at 6, 12, 18, 24, 36 and 60
months: the 28-joint count of tender joints (TJC) and
swollen joints (SJC); a Visual Analogue Scale (VAS)
score for pain and the patient’s global assessment; com-
pletion of a HAQ [34]; and measurement of inflamma-
tory markers, that is, erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP). The DAS28 score
was then calculated [35]. These data were downloaded
for the purposes of this study.
The therapeutic response was calculated according to the
European League Against Rheumatism (EULAR) response
criteria using the DAS28 score, thereby defining a response
to therapy as “good”, “moderate” or “none” [36]. The pres-
ence of autoantibodies, that is, rheumatoid factor (RF) and
antinuclear antibodies (ANAs), was assessed at baseline ac-
cording to the routine protocols in current use at each of
the participating hospitals. ACPAs were analysed at baseline
using enzyme-linked immunoassays for anti–cyclic citru-
llinated peptide 2 antibodies (Euro Diagnostica, Malmö,
Sweden). Genotyping for protein tyrosine phosphatase non-
receptor type 22 (PTPN22) 1858C/T polymorphisms and
patients positive for shared-epitope (SE) human leucocyte
antigen major histocompatibility complex, class II, DR β1
chain (HLA-DRB1*0401,0404,0405,0408 alleles), was per-
formed as previously described [37-39].
Radiographs of the hands, wrists and feet were ob-
tained at baseline and at 24 months according to the
recommendations of the Swedish Early RA Registry.
However, radiographs are randomly missing from one
centre and completely from three of the participating
centres. The radiographs were graded by two rheumatol-
ogists (SRD and EB) specially trained in the evaluation
of radiographs according to the Larsen score [40].
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the Larsen score at 24 months minus the Larsen score
at baseline was ≥3 (dichotomized at the median value of
this difference). The presence of erosions at T0 and at
24 months was also registered.
Additionally, all patient records were carefully exam-
ined and data collected according to a study protocol re-
garding co-morbidity and treatment, both at inclusion
(T0) and after five years (T5). The patients also com-
pleted a self-reported questionnaire on comorbidity at
T0 and T5 to increase further the validity of the col-
lected data. Recorded variables were cardiovascular dis-
ease (CVD) as previously described in detail [41], the
presence of hypertension (HT) and/or diabetes mellitus
(DM), smoking (currently and previously), the presence
of rheumatoid nodules and extra-articular disease [42]. Cu-
mulated pharmacological treatment was registered (months
before inclusion and during the follow-up period) regarding
corticosteroids and disease modifying anti-rheumatic drugs
(DMARDs, that is, methotrexate, sulphasalazine, chlo-
roquine, azathioprine, mycophenolate mofetil, myocrisin,
auranofin, cyclosporine, leflunomide, alkylating cytotoxic
agents) including biological agents (etanercept, adalimu-
mab, infliximab, anakinra, rituximab). Treatment with
non-steroidal anti-inflammatory drugs (NSAIDs), before
inclusion (T0) and any period during the follow up period
(T5), was recorded simply as “yes” or “no”.
Statistical analysis
Descriptive data collected at baseline and at 5 years are
presented as the mean (± standard deviation (SD)) or as a
percentage. Data analyses were based on stratification of
the patients according to median age (58 years) at the time
of disease onset as YORA (that is, <58 years) and LORA
(≥58 years). In patients with a single data point missing
from the Swedish Early RA Registry data, that is, ESR,
CRP, TJC/SJC, VAS score or HAQ score, the previous
value was used to impute data once for each inflammatory
variable assessed up to 24 months. The proportions of im-
putations for each variable and registration were 3.6%
from 0 to 6 months; however, that figure increased some-
what up to 24 months and is estimated to be, at most,
16%. Disease activity, based on DAS28 score, was calcu-
lated according to the trapezoid model [43] to evaluate the
total burden of disease activity over time, referred to as
the area under the curve (AUC) of DAS28 scores, at 6, 12
and 24 months after inclusion into the study. Compari-
sons of data between YORA and LORA were made with
independent and dependent t-tests and χ2 tests as appro-
priate. Multiple logistic regression analyses were first used
to evaluate the impact of known prognostic factors at
baseline, that is, disease activity (ESR), ACPA, comorbidity
and sex, together with age at disease onset, on a chosen
treatment, that is, DMARD treatment within 3 monthsfrom disease onset and corticosteroid treatment, as
dependent variables. Next, we tested the impact of a
chosen treatment, adjusted for prognostic risk factors, on
disease outcome, that is, radiological progression as
measured by the difference in the Larsen score (Δ = 0 to
24 months) dichotomized for the median value as the
dependent variable. Variables were initially chosen for
multiple modelling based on clinical assumptions and only
secondarily using the results from simple statistical ana-
lyses (P < 0.05). Correlation tests and standard errors indi-
cated no collinearity for the included variables in any of
the models. All P-values are two-sided, and P-values ≤0.05
were considered to be statistically significant. All calcula-
tions were performed using the IBM SPSS Statistics 21.0
software program (SPSS, Chicago, IL, USA).
Results
A total of 950 patients diagnosed with early RA were in-
cluded between December 1995 and February 2011 at the
five participating rheumatology centres. By 28 February
2011, 665 patients had been followed for 5 years (T5). All
patients could be tracked to the 5-year follow-up time
point. The median age at disease onset in this cohort of
patients was 58 years (range = 18 to 89 years).
Demographic data at baseline and after 5 years
Descriptive data for all patients, which were divided into
the two groups, that is, YORA (<58 years) and LORA
(≥58 years) are presented in Table 1. The total study
group of 950 patients at baseline (T0) comprised 357
women (75.2%) and 118 men (24.8%) in the YORA
patient group and 292 women (61.5%) and 183 men
(38.5%) in the LORA group. Among the patients who
reached the 5-year follow-up point (T5) (that is, n =
665), there were 262 women and 89 men in the YORA
group and 197 women and 117 men in the LORA group.
The mean duration (±SD) from the first sign of symp-
toms of rheumatoid disease until inclusion into the
Swedish Early RA Registry was 6.9 (±3.5) months for
YORA patients and 6.5 (±3.2) months for LORA pa-
tients (P = 0.048) with no sex differences, that is, 6.5
(±3.3) months for men and 6.8 (±3.6) months for
women (P = 0.265).
Autoantibodies, genetic markers and measures of disease
activity
Comparison between LORA and YORA patients re-
vealed that LORA was significantly associated with a
lower frequency of ACPA (Table 1) and less frequent
carriage of the PTPN22 T-variant. ACPA was more
common (66%) in the youngest quartile (18 to 47 years
of age), with a gradual decrease (65% in patients 48 to
58 years of age and 62% in patients 59 to 66 years of
age) to 50% in the oldest quartile (age range = 67 to 89
Table 1 Descriptive data for 950 patients with early rheumatoid arthritis at time of inclusion and at 5-year follow-upa
Variables YORA (N = 475) LORA (N = 75) P-value
Age at onset, yr <58 ≥58
Female, n (%) 357/475 (75.2) 292/475 (61.5)
Disease duration (mo) 6.90 (3.42) 6.45 (3.20) <0.05
RF+, n (%) 354/466 (75.9) 349/468 (75.6) NS
ANA+, n (%) 91/377 (24.2) 69/352 (19.6) NS
ACPA+ n (%) 313/429 (72.9) 267/411 (64.9) <0.05
PTPN22 T variant, n (%) 155/405 (38.3) 106/381 (27.8) <0.01
HLA-SE, shared epitope, n (%) 237/405 (58.5) 219/381 (57.5) NS
ESR at T0, mm/h (n = 948) 26.0 (21.5) 34.3 (24.2) <0,001
CRP at T0 mg/L (n = 888) 18.3 (23.7) 23.0 (24.6) <0.01
DAS28 at T0, (n = 788) 4.5 (1.5) 4.8 (1.4) <0.01
AUC DAS28 (6 mo)b 24.5 (7.2) 25.9 (7.0) <0.01
AUC DAS28 (12 mo)b 44.8 (13.4) 47.7 (13.2) <0.01
AUC DAS28 (24 mo)b 84.2 (26.8) 89.0 (23.3) <0.05
HAQ at T0, (n = 796) 0.81 (0.6) 0.92 (0.6) <0.01
Tender joints at T0 (n = 811) 6.3 (5.6) 6.5 (5.7) NS
Swollen joints at T0, (n = 812) 6.8 (5.2) 7.3 (5.2) NS
VAS pain at T0 (mm), (n = 800) 43.5 (25.5) 43.4 (25.9) NS
VAS global at T0 (mm) (n = 800) 44.0 (25.8) 45.0 (25.5) NS
Smoker (ever) T0, n (%) 287/443 (64.8) 300/447 (67.1) NS
Ex-RA ≤ T5, n (%)c,d 13/344 (3.8) 14/313 (4.5) NS
Nodules ≤ T5, n (%)c 60/312 (19.2) 38/275 (13.8) 0.079
DMARDs within 3 mo after T0, n (%)c,e 325/346 (93.9) 267/311 (85.9) <0.001
DMARDs (ever) ≤T5, n (%)c 344/348 (98.9) 299/310 (96.5) <0.05
Methotrexate (ever) ≤T5, n (%)c 313/346 (90.5) 253/311 (81.4) <0.001
Biologics (ever) ≤T5, n (%)c 84/342 (24.6) 23/310 (7.4) <0.001
NSAID T0, n (%) 317/455 (69.7) 297/466 (63.7) 0.056
NSAID ever ≤T5, n (%)c 307/340 (90.3) 233/307 (75.9) <0.001
COX-2-inhibitors at T0, n (%) 48/459 (10.5) 64/468 (13.7) NS
COX-2-inhibitors (ever) ≤T5, n (%)c 95/342 (27.8) 83/309 (26.8) NS
Corticosteroids T0 to T5 (mo)c 20.3 (23.8) 24.7 (23.8) <0.01
Corticosteroids (ever) ≤T5 (%)c 230/346 (66.5) 233/309 (75.4) <0.01
Hypertension at T0, n (%) 56/471 (11.9) 199/474 (41.9) <0.001
DM at T0, n (%) 22/464 (4.7) 54/470 (11.5) <0.001
CVD before T0, n (%)f 17/471 (3.6) 93/474 (19.6) <0.001
CVD related comorbidity at T0, n (%)g 86/475 (18.1) 238/475 (50.1) <0.001
Larsen score 0 (mo) (n = 437) 5.3 (5.8) 8.5 (6.2) <0.001
Larsen score 24 (mo) (n = 381) 9.5 (9.1) 12.5 (8.2) <0.001
Erosions 0 mo, n (%) 85/212 (40.1) 105/192 (54.7) <0.01
Erosions 24 mo, n (%) 107/173 (61.8) 119/158 (75.3) <0.01
Δ Larsen score 0 to 24 mo ≥3, n (%) 103/207 (49.8) 97/173 (56.1) 0.131
aACPA, Anticyclic citrullinated peptide/protein; ANA, Antinuclear antibody; AUC, Area under the curve; CVD, Cardiovascular disease; CRP, C-reactive protein; DAS28,
Disease Activity Score in 28 joints; DM, Diabetes mellitus; DMARD, Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; LORA, Late-onset rheumatoid arthritis; NS, Not significant; NSAID, Nonsteroidal anti-inflammatory drug; PTPN22, Protein tyrosine phosphatase nonreceptor
type 22; RA, Rheumatoid arthritis; RF, Rheumatoid factor; SD: Standard deviation; SE, Shared epitope; VAS, Visual Analogue Scale; YORA, Young-onset rheumatoid arthritis.
bAUC for DAS28 at 6 months after inclusion, YORA/LORA (n = 367/343); AUC for DAS28 at 12 months after inclusion, YORA/LORA (n = 308/281); AUC for DAS28 at 24
months after inclusion, YORA/LORA (n = 231/199). cPatients followed for 5 years (n = 665). dCriteria used for severe extraarticular manifestations: pericarditis, pleuritis,
interstitial lung disease, Felty’s syndrome, neuropathy, scleritis/episcleritis, glomerulonephritis, major cutaneous vasculitis and vasculitis involving other organs [42].
eDMARD treatment started within 3 months from baseline (T0). fCVD comorbidities as previously described in detail [41]. gCVD-related comorbidity at time of inclusion
(T0): CVD, hypertension or DM present before T0.
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Table 2 Age in relation to disease-modifying antirheumatic
drug treatment within 3 months after disease onseta
Covariates OR 95% CI P-value
Age at disease onsetb 0.403 0.217 to 0.749 <0.01
Female sex 1.002 0.535 to 1.878 0.994
ACPA-positive 1.484 0.812 to 2.712 0.199
ESR (T0), mm/h 1.027 1.009 to 1.045 <0.01
aACPA, Anticyclic citrullinated peptide/protein; CI: Confidence interval; DMARD,
Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate;
OR: Odds ratio. bAge at disease onset classified as young-onset rheumatoid
arthritis <58 years old and late-onset rheumatoid arthritis ≥58 years old. Data
are derived from multiple logistic regression (n = 562).
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HLA-SE (defined as HLA-DRB1*0401,0404,0405,0408
alleles) was not associated with age at disease onset.
Disease activity, measured by a combination of ESR,
CRP and accumulated Disease Activity Score (AUC for
DAS28) was higher in LORA patients than in patients
with disease onset at a younger age, as was greater re-
duction in physical function measured by HAQ score at
baseline (Table 1). The presence of extraarticular mani-
festations was similar in both groups, whilst rheumatic
nodules tended to be more common in YORA patients.
Radiographic findings at inclusion and at 2 years
Radiographs of the hands, wrists and feet were taken at
baseline for 230 YORA and 207 LORA patients and at 2
years for 208 YORA and 173 LORA patients. LORA was
significantly more often associated with the presence of
erosions and a higher Larsen score at both time 0 and at
24 months (Table 1). Both YORA and LORA patients
exhibited radiological progression as measured by an in-
crease in Larsen scores over time (YORA = 5.31 (±5.8)
vs. 9.46 (±9.04) and LORA = 8.14 (±5.81) vs. 12.45
(±8.22); P < 0.001 for both). Additionally, the presence
of erosions increased significantly between 0 and 24
months in both groups (YORA 40.1% vs. 61.8% and
LORA 54.7% vs. 75.3%; P < 0.001). However, there was
no statistically significant difference between YORA and
LORA patients in terms of progression of the Larsen
scores or the presence of erosions (data not shown).
Pharmacological treatment and cardiovascular disease
comorbidity at baseline and at 5 years
LORA was associated with less frequent treatment
with DMARDs, particularly early in the disease process
(Table 1). LORA was also associated with significantly less
treatment with methotrexate and biologics and more fre-
quent treatment with corticosteroids (Table 1). A reduc-
tion in the DAS28 score during the first 24 months was
numerically larger in LORA than in YORA (1.72 (±1.57)
vs. 1.44 (±1.71); P = 0.058). With regard to EULAR re-
sponse criteria, 26% of patients with LORA were classified
as “nonresponders,” compared with 36.7% of YORA pa-
tients, at 12 months (P < 0.01). Comorbidity, such as HT,
DM and CVD, was present significantly more often in
LORA patients (P < 0.001) (Table 1).
Multiple logistic regression models
The impact of age at disease onset was tested in relation
to the choice of treatment, that is, early treatment with
DMARDs (within 3 months following the onset of dis-
ease) and with corticosteroids, respectively, in multiple
regression models. In baseline models adjusted for sex,
ACPA status and disease activity (measured by ESR),
YORA was significantly associated with early DMARDtreatment (Table 2) and LORA was associated with cor-
ticosteroid treatment (Table 3). Age was also related to the
chosen drug treatment when tested as a continuous vari-
able (odds ratio (OR) = 0.969, 95% confidence interval
(CI) = 0.945 to 0.993, P < 0.01 for early DMARD treat-
ment; OR = 1.021, 95% CI = 1.006 to 1.035, P < 0.01 for
corticosteroid treatment). In addition, the results were
similar regarding age at the onset of disease when the data
were corrected for baseline comorbidity (OR = 0.371, 95%
CI = 0.194 to 0.709, P < 0.01 for early DMARD treatment
as the dependent variable; OR = 1.453, 95% CI = 0.967 to
2.183, P = 0.072 for corticosteroids) (Additional file 1:
Table S1 and Additional file 2: Table S2).
Regarding radiological progression over 24 months as the
response variable, ACPA status and older age at disease on-
set (LORA) were significantly associated with progression
of Larsen score of ≥3 (0 to 24 months) in multiple models
adjusted for age, sex, ACPA status, disease activity (based
on ESR), comorbidity at baseline and chosen therapy, that
is, early treatment with DMARDs (Table 4) and corticoste-
roids (Table 5), respectively. In these multiple models, male
sex was significantly related to greater radiological progres-
sion at 24 months (Tables 4 and 5).
In these multiple models, male sex was significantly re-
lated to a greater radiological progression at 24 months
(Tables 4 and 5).
Discussion
Our objective in the present study was to describe the
impact of age at the onset of RA on prognostic risk fac-
tors, disease severity and chosen treatment early in the
disease process. LORA (that is, age ≥58 years) was asso-
ciated with greater disease activity and radiographic
changes at disease onset. Also, inflammatory activity
over time and functional impairment were greater in pa-
tients with LORA. Nevertheless, YORA (that is, <58
years of age) was more frequently associated with early
treatment with DMARDs and biologics compared with
LORA patients, who were treated more often with corti-
costeroids but less often with DMARDs during the first
3 months following disease onset. These findings, taken
Table 3 Age in relation to corticosteroid treatmenta
Covariates OR 95% CI P-value
Age at disease onsetb 1.540 1.045 to 2.267 <0.05
Female sex 0.803 0.529 to 1.219 0.304
ACPA-positive 1.127 0.752 to 1.693 0.565
ESR (T0), mm/h 1.011 1.002 to 1.020 <0.05
aACPA, Anticyclic citrullinated peptide/protein; CI: Confidence interval; ESR,
Erythrocyte sedimentation rate; OR: Odds ratio. bAge at disease onset classified
as young-onset rheumatoid arthritis <58 years old and late-onset rheumatoid
arthritis ≥58 years old. Data are derived from multiple logistic regression
(n = 574).
Table 5 Age in relation to radiological progressiona
Covariates OR 95% CI P-value
Age at disease onsetb 1.842 1.014 to 3.348 <0.05
Female sex 0.361 0.189 to 0.692 <0.01
ACPA-positive 2.473 1.282 to 4.769 <0.01
ESR (T0), mm/h 1.010 0.997 to 1.024 0.136
CVD-related comorbidityc 0.889 0.460 to 1.718 0.727
Corticosteroids (ever) ≤T5, yes 0.892 0.488 to 1.631 0.711
aACPA, Anticyclic citrullinated peptide/protein; CI: Confidence interval; CVD,
Cardiovascular disease; DMARD, Disease-modifying antirheumatic drug; ESR,
Erythrocyte sedimentation rate; OR: Odds ratio. bAge at disease onset stratified
as young-onset rheumatoid arthritis <58 years old and late-onset rheumatoid
arthritis ≥58 years old. bCVD-related comorbidity at time of inclusion (T0): CVD,
hypertension or diabetes mellitus present before T0. cRadiological progression
is defined as the difference between Larsen score at 24 months and Larsen
score at baseline (Δ Larsen score) ≥3. Data are derived from multiple logistic
regression (n = 236).
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portant for the prognosis and development of comorbid-
ities in the long term.
In this study, the YORA patients were significantly
more often positive for ACPA, an autoantibody that is
associated with worse disease progression [9,10]. Fur-
thermore, the prevalence of ACPA decreased with in-
creasing age at onset of RA. The YORA patients were
also more frequently carriers of the PTPN22 T-variant
compared with LORA patients. In a previous study, we
found carriage of the PTPN22 T-variant and presence of
ACPA to be independently associated with disease onset
at an earlier age (P < 0.05 and P < 0.01, respectively),
whilst the combination of both was associated with an
even younger age at disease onset [39]. In the present
study, the frequency of RF and HLA-SE positivity was
similar for both the YORA and LORA cohorts, which is
consistent with previously published findings by van der
Heijde and colleagues [22]. We found that LORA was
more often associated with the presence of erosions and
a higher Larsen score, both at baseline and after 2 years.
These findings are also in line with those presented by
van der Heijde et al., who found a tendency towards
more radiographically detected damage in older patientsTable 4 Age in relation to radiological progressiona
Covariates OR 95% CI P-value
Age at disease onsetb 2.019 1.084 to 3.761 <0.05
Female sex 0.368 0.188 to 0.722 <0.01
ACPA-positive 2.179 1.117 to 4.251 <0.05
ESR (T0), mm/h 1.008 0.995 to 1.022 0.231
CVD-related comorbidityc 0.838 0.420 to 1.675 0.671
DMARD treatment within
3 month after T0, yes
1.400 0.594 to 3.298 0.442
aACPA, Anticyclic citrullinated peptide/protein; CI: Confidence interval; CVD,
Cardiovascular disease; DMARD, Disease-modifying antirheumatic drug; ESR,
Erythrocyte sedimentation rate; OR: Odds ratio. bAge at disease onset stratified
as young-onset rheumatoid arthritis <58 years old and late-onset rheumatoid
arthritis ≥58 years old. cCVD-related comorbidity at time of inclusion (T0): CVD,
hypertension or diabetes mellitus present before T0. Radiological progression is
defined as the difference between Larsen score at 24 months and Larsen score
at baseline (Δ Larsen score) ≥3. Data are derived from multiple logistic regression
(n = 227).compared with patients younger than 60 years of age at
follow-up [22]. Furthermore, Bukhari et al. showed that
an older age at the onset of symptoms was associated
with an increased occurrence of erosions during the first
12 months in patients diagnosed with early polyarthritis
[14]. We also found that a raised HAQ score at baseline
was associated with LORA. This finding is similar to that
reported by Pease et al., who found that patients over 65
years of age had a higher HAQ score at baseline [11],
and with results derived from the Norfolk Arthritis
Register showing that more advanced age at symptom
onset was associated with a “steep trajectory” progres-
sion of disability [44]. Taken together, our findings indi-
cate a phenotype more predisposed to progressive
disease related to ACPA positivity and PTPN22 poly-
morphism in patients whose onset of disease occurs at a
younger age. Nevertheless, the radiological findings and
the functional capacity are worse in patients with a later
onset. We also found a worse radiologically detectable
disease progression in males, thus confirming our find-
ings in a previous study [45] and meriting further
investigation.
A late onset of RA was associated with a higher
DAS28 score calculated at baseline. However, a reduc-
tion in DAS28 score after 24 months was somewhat
greater in patients with LORA in comparison to those
with YORA. Also, when the data were stratified for re-
sponse to therapy using the EULAR response criteria
[36], LORA patients had a significantly better response
after 12 months than patients with YORA. The LORA
patients in the present study were more often treated
with corticosteroids, which are known to have a capacity
to rapidly reduce disease activity, early in the course
of disease progression. Despite receiving such therapy,
LORA patients more often had erosions and a higher
Larsen score at 24 months. Late onset-disease was asso-
ciated with less frequent treatment with methotrexate
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frequent treatment with DMARDs early in the disease
process, that is, within 3 months from inclusion into the
study. Apparently, treatment with corticosteroids re-
duced inflammatory activity efficiently but could not
compensate for the less frequent DMARD treatment
early in the disease course in the patients with late-onset
disease in terms of radiological status at 24 months.
Radiological progression appeared without regard to the
chosen drug treatment. It is conceivable that a more evi-
dent impact of the chosen treatment would be demon-
strable in a larger cohort or with a longer follow-up
period. There was no delay in the diagnosis of the LORA
patients, with the disease duration being somewhat
shorter in this group. Coexisting osteoarthritis could
contribute to the worse radiographic status in LORA pa-
tients, as could the possibility of cartilage that is more
susceptible to damage in elderly individuals, as has been
suggested by others [11,14]. However, our finding of a
greater Larsen score cannot be explained simply by the
progression of cartilage damage as part of osteoarthritis,
because there was also a significant progression of the
erosions over time in LORA patients. Thus, the treat-
ment of LORA patients with corticosteroids did not re-
duce radiological progression, despite the positive effects
of these drugs on inflammatory activity. Treatment with
low doses of prednisolone as a monotherapy, or in com-
bination with DMARDs, has previously been reported to
have positive effects with respect to the remission rate
and inhibition of radiographic progression [46-48]. How-
ever, contrasting results were reported by Paulus et al.,
who found that monotherapy with low-dose corticoste-
roids did not prevent radiological progression [49].
Earlier studies generally concluded LORA to be a mild
disease with a good prognosis [16-19] but several more re-
cent studies have shown equal, or worse, disease activity
and severity in older patients compared with younger pa-
tients [11-15,22,50]. In, agreement with Swedish guidelines
[26], and similar to EULAR [27] and American College
of Rheumatology guidelines [28], we treat patients with
DMARDs, primarily methotrexate, in combination with
low doses corticosteroids if their disease activity is consid-
ered to be “high to moderate” at disease onset. Neverthe-
less, our study shows that age at disease onset influences
the choice of pharmacological treatment. According to our
results, rheumatologists are less likely to treat LORA pa-
tients with DMARDs within 3 months from disease onset
compared with YORA. Anderson et al. [51] reported that
patients with longer disease durations did not respond to
treatment to the same extent as patients with early disease,
thus giving additional support to the observation that early
DMARD therapy modulates inflammation more effect-
ively. One possible explanation for later initiation of
DMARD treatment is that LORA patients tend to havemore comorbidities and coexisting diseases requiring
treatment with other drugs. However, when comorbidity
at baseline was also taken into account, the choice of treat-
ment was associated with age at onset of disease.
Early in the disease course, it is easy and efficient to
control disease activity by using corticosteroid treat-
ment. Both the clinician and the patient may be pleased
with the rapid relief of symptoms achieved with cortico-
steroid treatment, and there is more concern about the
potential side effects of DMARDs in older patients. At
times, this clinical decision may be correct, and a risk vs.
benefit profile must always be taken into consideration.
Treatment with corticosteroids can be precarious in eld-
erly patients and should be evaluated with respect to in-
creased risk of adverse effects, such as osteoporosis,
infection, diabetes, peptic ulcers, cataract and HT [52].
In the current literature, data are still lacking regarding
the net effect of corticosteroids in patients with inflam-
mation. Several studies have shown that treatment with
methotrexate, sulphasalazine and antimalarial therapy,
and other DMARDs is well-tolerated by the elderly [50].
Tutuncu and co-workers showed that toxicity due to
methotrexate and biological agents was very low in all
patients studied, regardless of age [13]. In that study, pa-
tients with LORA were also treated significantly less
often with biological agents compared with YORA pa-
tients. This observation is consistent with recently pub-
lished findings of Huscher et al. [53]. Recent studies
have shown that biological therapy can be used in the
treatment of elderly patients, but risk factors for adverse
effects should be evaluated extra carefully before starting
any therapy [54,55].
The strengths of the present study are the patient group,
which consists of a large regional cohort, and its prospect-
ive design. The study involves few physicians at each
rheumatology centre in northern Sweden. In Sweden, es-
sentially all patients with newly diagnosed RA are referred
to a specialist. Thus, the results derived from the present
cohort can be regarded as applicable to all patients with
early RA. Furthermore, repeated measurement of the pa-
rameters associated with inflammation made it possible to
take into account variability in disease activity. Conversely,
a limitation of the study is its observational nature, with a
risk of confounding by indication when evaluating the effi-
ciency of pharmacological treatment. We attempted to ad-
just for that possibility by using multiple regression
modelling in the statistical analyses when evaluating po-
tential covariates in relation to LORA.
Conclusions
LORA was associated with greater incipient disease activ-
ity, reduced function at baseline and more radiological
damage at disease onset and over time. Nevertheless, such
patients were more often treated with corticosteroids and
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pared with the YORA patients. We propose that patients
with LORA should receive the same treatment as younger
patients at the onset of disease; however, such patients
may require tighter controls to rapidly detect any potential
complicating comorbidity or other undesirable side effects
of the treatment.
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